Truist Securities Reiterates Buy on Pfizer, Maintains $62 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Pfizer (NYSE:PFE) and maintained a price target of $62.
September 13, 2023 | 2:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer's stock is reiterated as a 'Buy' by Truist Securities with a maintained price target of $62.
The reiteration of a 'Buy' rating by Truist Securities indicates a positive outlook for Pfizer's stock. The maintained price target of $62 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100